The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat

Схожі ресурси

• Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
  за авторством: Jendle, J, та інші
  Опубліковано: (2009)
• Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced body weight compared with glimepiride when added to metformin
  за авторством: Hermansen, K, та інші
  Опубліковано: (2008)
• Liraglutide improves adipose tissue remodeling and mitochondrial dynamics in a visceral obesity model induced by a high-fat diet
  за авторством: Vanessa Touceda, та інші
  Опубліковано: (2024-01-01)
• Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
  за авторством: Nauck, M, та інші
  Опубліковано: (2009)
• Fat tissue engineering : development of hybrid fat grafts
  за авторством: Ting, Hui Lin
  Опубліковано: (2015)